Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
(University of Colorado Anschutz Medical Campus) Pooled analysis of three phase 1 and 2 clinical trials show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Neurology | Non-Small Cell Lung Cancer